Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
maybe. but you're still down 90+ percent or so, right?
Because that was a fake deal. SELLAS never had the financial or intellectual wherewithal to do anything with ADXS tech, if you can call it that.
But that isn't what happened. They brought in zero $ and diluted shareholders with the exchange of shares for warrants.
presumably not criminal but...
The number of authorized shares is unaffected by the reverse split. Not the least bit bullish. Pay attention.
Hope isn't a good investment thesis.
presumably because their algorithms noticed that the stock is trading below cash. an anachronistic situation, to be sure. in the case of adxs, however, it is clearly warranted.
it hardly matters from an investment standpoint considering the impending dilutions / reverse splits.
Isn't another reverse split followed by another massive dilution the most likely outcome?
This company has to restructure, again.
The only other somewhat likely outcome is an outright sale.
They have no other options. Think about it.
abandon all hopes. down 10% on 200$ traded . boom.
no news is bad news.
Do you trust the American Ponzi scheme known as Advaxis?
ding! ding! ding! this.
still long?
Ea$y short. Thanks!
still long, dew?
without regard as to whether their tech works, they have to recapitalize. they've telegraphed their intention to do so.
current shareholders are in peril. this is indisputable. you are the stakeholders who don't matter.
without regard as to whether their tech works, they have to recapitalize. they've telegraphed their intention to do so.
current shareholders are in peril. this is indisputable. you are the stakeholders who don't matter.
Presumably, something that isn't going to lose 100% of it's current value next year.
Venezuelan currency has been a better investment than ADXS.
Delay?
without regards to the technology, it's obvious where this stock is going. to zero.
ZERO
hmmm. i wonder what would happen on the off chance it was voted down.
sorry i can't vote "no". again.
...we do not have sufficient authorized shares available to settle all of our currently outstanding equity awards or to grant new equity awards...
advaxis is looking for someone to sublet while they wind down. i presume. if thats what you mean by partner.
This is precisely what will happen. It's called liquidation. All proceeds to severance packages. Zero to shareholders.
clearly, a failed experiment.
At a 52 week low, at a price 50% lower than it was on Oct 02, 2018.
120% bonuses for all!
Dear SEC,
I bought stock in a failed company. I fell for the story but ignored the fundamentals. Do something!
Unfortunate, but highly predictable.
over a decade ago? you must be down 99.99%
take your tax loss. give up already.
but it's such a great story. unbelievable technology. thinking about things like capital structure, dilution, and liquidity makes my brain hurt so i don't do it.
supermolecule like the others 5 billion dollars ago?
Why do you think the "drag of litigation" has been mitigated?
Hey, buddy!
Good luck. There's some pretty strong downside resistance in the $12 area.
reminds me of merck's acquisition of idenix.
and the subsequent 3 billion dollar write off.
mtna gonna mtna
jbog wins again, flubo!
Right. I should have prefaced with:
"The value of..."
and finished with:
"... their analytical capabilities has been over-stated, mishandled, or wasted."
They're analytical capabilities may have been over-stated.
As always, the lawyers prepped CW well. He was on script.
That said, my take is that there isn't a clawback/pay off problem with Mylan.
There was some implication that due to the regulatory/business climate, some foreign investors weren't allowed to or didn't want to play in the "restructuring". Also, that future deals would not be for multiple drugs (due to the overlapping products problems encountered when trying to dump the biosimilar arm all together) .
Of course, I may have misinterpreted everything.
It's a short call.